| scholarly article | Q13442814 |
| P2093 | author name string | Takeshi Mori | |
| Hiroshige Mikamo | |||
| Mao Hagihara | |||
| Takumi Umemura | |||
| P2860 | cites work | Teicoplanin versus vancomycin for proven or suspected infection | Q24234764 |
| Teicoplanin metabolism in humans | Q24671805 | ||
| Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users | Q24675979 | ||
| Interaction of daptomycin with two recombinant thromboplastin reagents leads to falsely prolonged patient prothrombin time/International Normalized Ratio results | Q46818884 | ||
| The association between biocide tolerance and the presence or absence of qac genes among hospital-acquired and community-acquired MRSA isolates | Q46915288 | ||
| Exploration of optimal teicoplanin dosage based on pharmacokinetic parameters for the treatment of intensive care unit patients infected with methicillin-resistant Staphylococcus aureus. | Q51024693 | ||
| Spread of the community-acquired methicillin-resistant Staphylococcus aureus USA300 clone among family members in Japan. | Q54342896 | ||
| Methicillin-ResistantS. aureusInfections among Patients in the Emergency Department | Q55897489 | ||
| Effectiveness and nephrotoxicity of colistin monotherapy vs. colistin-meropenem combination therapy for multidrug-resistant Gram-negative bacterial infections | Q79377177 | ||
| [Combined effect of vancomycin or teicoplanin plus a beta-lactam antibiotic in mouse infection models caused by beta-lactam antibiotec-induced vancomycin resistant MRSA (BIVR)] | Q79739984 | ||
| Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001-05 | Q80595494 | ||
| An association between reduced susceptibility to daptomycin and reduced susceptibility to vancomycin in Staphylococcus aureus | Q83230645 | ||
| Clinical characteristics of vancomycin minimum inhibitory concentration of 2 μg/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia | Q84563829 | ||
| An initial dosing method for teicoplanin based on the area under the serum concentration time curve required for MRSA eradication | Q84749727 | ||
| National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. | Q30977541 | ||
| Higher linezolid exposure and higher frequency of thrombocytopenia in patients with renal dysfunction | Q33389145 | ||
| Hospitalizations and deaths caused by methicillin-resistant Staphylococcus aureus, United States, 1999-2005 | Q33877838 | ||
| Short-course gentamicin in combination with daptomycin or vancomycin against Staphylococcus aureus in an in vitro pharmacodynamic model with simulated endocardial vegetations | Q33883648 | ||
| Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus | Q34558111 | ||
| Genetic changes that correlate with reduced susceptibility to daptomycin in Staphylococcus aureus | Q34680589 | ||
| Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio | Q34737606 | ||
| Daptomycin Dose-Effect Relationship against Resistant Gram-Positive Organisms | Q34936759 | ||
| In vivo pharmacodynamic activity of daptomycin | Q35005549 | ||
| Population pharmacokinetics of Arbekacin in patients infected with methicillin-resistant Staphylococcus aureus | Q35127932 | ||
| Correlation of daptomycin bactericidal activity and membrane depolarization in Staphylococcus aureus | Q35166213 | ||
| Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin | Q35758808 | ||
| Lipopeptides, focusing on daptomycin, for the treatment of Gram-positive infections | Q35871928 | ||
| Characterization of a daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus strain in a patient with endocarditis. | Q36094925 | ||
| Transcriptional profiling reveals that daptomycin induces the Staphylococcus aureus cell wall stress stimulon and genes responsive to membrane depolarization | Q36482900 | ||
| Population pharmacokinetics of daptomycin | Q36670451 | ||
| Daptomycin disrupts membrane potential in growing Staphylococcus aureus | Q36756893 | ||
| Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates | Q36972978 | ||
| Efficacy of daptomycin in implant-associated infection due to methicillin-resistant Staphylococcus aureus: importance of combination with rifampin | Q37247663 | ||
| Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin, in an in vitro pharmacodynamic model | Q37625071 | ||
| Linezolid versus vancomycin for the treatment of gram-positive bacterial infections: meta-analysis of randomised controlled trials | Q37630016 | ||
| Once-daily dosing in dogs optimizes daptomycin safety | Q39537062 | ||
| In vitro activities of daptomycin, vancomycin, quinupristin- dalfopristin, linezolid, and five other antimicrobials against 307 gram-positive anaerobic and 31 Corynebacterium clinical isolates | Q39730584 | ||
| Efficacy of Daptomycin in Experimental Endocarditis Due to Methicillin-Resistant Staphylococcus aureus | Q39746366 | ||
| Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs | Q40087244 | ||
| In vitro pharmacodynamics of vancomycin and cefazolin alone and in combination against methicillin-resistant Staphylococcus aureus | Q40326741 | ||
| Linezolid treatment for intracranial abscesses caused by methicillin-resistant Staphylococcus aureus--two case reports | Q40355151 | ||
| Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus | Q40542104 | ||
| Synergy of daptomycin with oxacillin and other beta-lactams against methicillin-resistant Staphylococcus aureus | Q41269406 | ||
| Induction of daptomycin heterogeneous susceptibility in Staphylococcus aureus by exposure to vancomycin | Q42042890 | ||
| Correlation between Reduced Daptomycin Susceptibility and Vancomycin Resistance in Vancomycin-Intermediate Staphylococcus aureus. | Q42112490 | ||
| Treatment outcomes for serious infections caused by methicillin-resistant Staphylococcus aureus with reduced vancomycin susceptibility | Q43433837 | ||
| The in vitro activity of daptomycin against 514 Gram-positive aerobic clinical isolates | Q43693099 | ||
| Epidemiological investigation of "beta-lactam antibiotic induced vancomycin-resistant MRSA (BIVR)" | Q44557982 | ||
| An evaluation of the P450 inhibition and induction potential of daptomycin in primary human hepatocytes | Q45145643 | ||
| Rhabdomyolysis and acute renal failure associated with the co-administration of daptomycin and an HMG-CoA reductase inhibitor | Q46061131 | ||
| Consequences of daptomycin-mediated membrane damage in Staphylococcus aureus | Q46453501 | ||
| Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact | Q46494181 | ||
| Effects of prior effective therapy on the efficacy of daptomycin and ceftriaxone for the treatment of community-acquired pneumonia | Q46620650 | ||
| Effect of antibiotics, alone and in combination, on Panton-Valentine leukocidin production by a Staphylococcus aureus reference strain. | Q46763814 | ||
| P275 | copyright license | Creative Commons Attribution-NonCommercial 3.0 Unported | Q18810331 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | methicillin-resistant Staphylococcus aureus | Q595158 |
| Staphylococcus aureus | Q188121 | ||
| P304 | page(s) | 79-86 | |
| P577 | publication date | 2012-02-17 | |
| P1433 | published in | Therapeutics and Clinical Risk Management | Q15766913 |
| P1476 | title | Daptomycin approved in Japan for the treatment of methicillin-resistant Staphylococcus aureus | |
| P478 | volume | 8 |
Search more.